2022
Safety considerations with the current treatments for peripheral T-cell lymphoma
Sethi T, Montanari F, Foss F. Safety considerations with the current treatments for peripheral T-cell lymphoma. Expert Opinion On Drug Safety 2022, 21: 653-660. PMID: 35129014, DOI: 10.1080/14740338.2022.2036120.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsPeripheral T-cell lymphomaT-cell lymphomaCombination chemotherapyTreatment regimensAnthracycline-based combination chemotherapyNK-T cell lymphomaB-cell non-Hodgkin lymphomaSingle-agent chemotherapyAvailable treatment regimensNon-Hodgkin lymphomaT cell subtypesSelection of agentsRelapsed settingAgent chemotherapyNatural killerFrontline treatmentPoor prognosisDisease groupUnique immunobiologyCurrent treatmentCell lymphomaCell disordersSide effectsLymphomaCertain complications
2019
Clinicopathologic correlates of MYD88 L265P mutation and programmed cell death (PD-1) pathway in primary central nervous system lymphoma
Sethi TK, Kovach AE, Grover NS, Huang LC, Lee LA, Rubinstein SM, Wang Y, Morgan DS, Greer JP, Park SI, Thompson-Arildsen M, Yenamandra A, Vnencak-Jones CL, Reddy NM. Clinicopathologic correlates of MYD88 L265P mutation and programmed cell death (PD-1) pathway in primary central nervous system lymphoma. Leukemia & Lymphoma 2019, 60: 2880-2889. PMID: 31184237, PMCID: PMC7280020, DOI: 10.1080/10428194.2019.1620942.Peer-Reviewed Original ResearchMeSH KeywordsAllelesAmino Acid SubstitutionBiomarkers, TumorCentral Nervous System NeoplasmsCombined Modality TherapyGenetic Association StudiesGenetic Predisposition to DiseaseHumansImmunohistochemistryIn Situ Hybridization, FluorescenceLymphocytes, Tumor-InfiltratingMacrophagesMutationMyeloid Differentiation Factor 88Neoplasm StagingPrognosisProgrammed Cell Death 1 ReceptorSignal TransductionSurvival AnalysisT-LymphocytesConceptsPD-1PD-L1Positive tumorsClinicopathologic correlatesT cellsPrimary central nervous system lymphoma (PCNSL) patientsPrimary central nervous system lymphomaPD-L1 positive tumorsEpstein-Barr virus infectionCentral nervous system lymphomaPotential targetable pathwayPD-L1 expressionProtein expressionNervous system lymphomaMyD88 protein expressionMYD88 L265P mutationSystemic lymphomaSystem lymphomaLymphoma patientsMacrophage infiltrationPoor prognosisVirus infectionTargetable pathwaysL265P mutationPathway alterations